Interview with Jan Slob, President, Akrikhin
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
Address: 52, bld 5, Kosmodamianskaya Naberezhnaya,Moscow, Russia, 115054,Russia
Tel: + 7 (495) 721 36 97
AKRIKHIN founded in 1936, is one of the leading Russian pharmaceutical producer of high-quality medicines on the Russian pharmaceutical market. By 2010 results AKRIKHIN is the 5th largest local producer by revenue and production volume on the Russian pharmaceutical market.
AKRIKHIN product portfolio counts more than 150 products focused within strategically selected Anatomo Therapeutic Classes including cardiovascular, neurology, dermatology, gynecology, pediatrics. AKRIKHIN produces a wide range of socially important medications thus making a tangible input into the development of the Russian healthcare system. AKRIKHIN is a major Russian producer of Essential Drugs which account up to 70% share of the Company product portfolio. Special emphasis is made on strategic directions of high social value – production of drugs for diabetes and tuberculosis treatment.
With the Company Field Force operating in 76 cities all across Russia and highly professional marketing team AKRIKHIN has succeeded in forming a wide and well-diversified product portfolio well recognized by doctors.
AKRIKHIN production facilities is a consolidated GMP-oriented complex located 30 km from Moscow with the workshops for production of a vast spectre of drug forms: tablets, capsules, ointments, gels, creams, syrups, etc. AKRIKHIN production existing capacities amount to more than 50 mln packs per year.
Starting from 2007 AKRIKHIN entered a strategic alliance with Polpharma – the largest Polish manufacturer of generic drugs and pharmaceutical substances. AKRIKHIN and Polpharma strategic partnership embracesincorporates common product portfolio, production technologies transfer, R&D cooperation, access to best European practices and standards, joint educational programmes for personnel.
In the “Rating of influence of Russian pharmaceutical market participants” based on pharmaceutical market experts’ opinions “AKRIKHIN” is included into the TOP 3 most authoritative and influential Russian pharmaceutical producers upon the results of 2010.
AKRIKHIN priding on its 75-years’ history and traditions builds on its successful performance on the Russian pharmaceutical market, dynamically adapting itself to modern business practices and technologies.
In its portfolio of more than 150 products of various dosage forms: tablets, capsules, creams, suppositories, creams, syrups. Akrihin focuses on therapeutic areas with high social importance, ie most sought-after Russian health care system: cardiology, diabetes, neurology, dermatology, tuberculosis, gynecology and pediatrics
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here